Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 4Not yet recruiting 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Advanced Cancers 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Injections, Subcutaneous × Clear all
NCT07260708 2026-04-21

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
42 enrolled

Advanced Cancers

NCT07179679 2025-12-11

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
42 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡